ArticlePLOS global public health2025
Subcutaneous injections of penicillin (SCIP): Convenient and effective treatment for Māori, Pacific Peoples and their families in preventing rheumatic heart disease.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) remain significant health issues for Māori and Pacific communities in Aotearoa New Zealand (NZ). Subcutaneous injection of penicillin (SCIP) enables injections to be given 10-weekly as an alternative to the standard four-weekly intramuscular (IM) injections. As part of a clinical trial involving participants with ARF who have been on SCIP for at least one year, we aim to explore treatment adherence, pain management, and quality of life for Māori and Pacific participants and their families (whānau). A community centred approach aligned with Kaupapa Māori, and Pacific-centred research values was used. Semi-structured interviews were conducted with 10 families, including nine participants on SCIP. Data collection occurred between March and August 2024. Thematic analysis was used to identify key themes from participants' experiences. Six themes emerged: Reduced burden of treatment; emotional impact from reduced injection frequency; family-centered care by healthcare providers; relationship building (whakawhanaungatanga); health literacy; and pain management. Participants valued SCIP's 10-week dosing interval, which contributed to improvements in quality of life. The extended dosing interval also alleviated emotional barriers, including the stress associated with more frequent injections. Participants valued that nurses offered them the choice of which location to receive their injections, at home, in a clinic, at work, or at school. Strong relationships with healthcare providers, especially research nurses, were essential for adherence. This study highlights that the extended dosing interval provided by SCIP reduced the physical and emotional burdens participants experienced with their monthly IM BPG injections, thereby enhancing quality of life. The findings emphasise the importance of culturally responsive, family-centered models of care. SCIP offers an opportunity to improve adherence to secondary prophylaxis and if implemented as a standard treatment option, improve health outcomes both in NZ and internationally.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.